Regenerative medicine company Stem Health Plus has unveiled its advanced stem cell skin graft technology for the skin regeneration sector.
The proprietary technology addresses burn recovery, chronic wounds, and cosmetic skin repair and transforms medical care and recovery, said the company.
Stem Health Plus said traditional skin grafting techniques have slow recovery, high infection risks, and poor aesthetic outcomes. The regenerative medicine company is advancing this process with stem cell technology.
The technology also accelerates healing, reduces scarring, and enhances skin regeneration quality.
This advanced stem cell technology has a significant impact in several key areas. In burn recovery, it accelerates healing for severe burns by promoting faster tissue regeneration and minimising scarring.
For chronic wound care, such as diabetic ulcers and other non-healing wounds, stem cell solutions stimulate tissue regeneration where traditional treatments often fall short.
Additionally, in cosmetic and reconstructive applications, it offers patients a way to reduce scars, improve skin texture, and restore damaged skin.
Stem Health Plus combines advanced stem cell biology with advanced medical practices.
The firm focuses on improving recovery outcomes and addressing the emotional and psychological impact of skin damage on patients.
Beyond providing transformative treatments, the company is dedicated to advancing regenerative medicine. It is also expanding the boundaries of skin repair and wound care via continuous research and collaboration with medical professionals.
Stem Health Plus’s solutions are available to healthcare providers in the US, ensuring that patients across the country can access this technology.
In a similar development, in November last year, StemCyte secured the US Food and Drug Administration (FDA) approval for its Biologics License Application (BLA) for Regenecyte.
Regenecyte is an allogeneic hematopoietic progenitor cell (HPC) therapy derived from cord blood. It is designed for transplantation in patients with blood and immune system disorders.
